(Q51910874)

English

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial.

scientific article published in July 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

17 April 2018

http://europepmc.org/abstract/MED/17617271

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. (English)

1 reference

Europe PubMed Central

17 April 2018

http://europepmc.org/abstract/MED/17617271

0 references

1 reference

based on heuristic

inferred from title

Adriano Lazzarin

object named as

Adriano Lazzarin

1

0 references

Bonaventura Clotet Sala

3

object named as

Bonaventura Clotet

1 reference

Europe PubMed Central

17 April 2018

Christine Katlama

5

object named as

Christine Katlama

1 reference

Europe PubMed Central

17 April 2018

author name string

Thomas Campbell

2

1 reference

Europe PubMed Central

17 April 2018

http://europepmc.org/abstract/MED/17617271

Margaret Johnson

4

1 reference

Europe PubMed Central

17 April 2018

http://europepmc.org/abstract/MED/17617271

Arend Moll

6

1 reference

Europe PubMed Central

17 April 2018

http://europepmc.org/abstract/MED/17617271

William Towner

7

1 reference

Europe PubMed Central

17 April 2018

http://europepmc.org/abstract/MED/17617271

Benoit Trottier

8

1 reference

Europe PubMed Central

17 April 2018

http://europepmc.org/abstract/MED/17617271

Monika Peeters

9

1 reference

Europe PubMed Central

17 April 2018

http://europepmc.org/abstract/MED/17617271

Johan Vingerhoets

10

1 reference

Europe PubMed Central

17 April 2018

http://europepmc.org/abstract/MED/17617271

Goedele de Smedt

11

1 reference

Europe PubMed Central

17 April 2018

http://europepmc.org/abstract/MED/17617271

Benny Baeten

12

1 reference

Europe PubMed Central

17 April 2018

http://europepmc.org/abstract/MED/17617271

Greet Beets

13

1 reference

Europe PubMed Central

17 April 2018

http://europepmc.org/abstract/MED/17617271

Rekha Sinha

14

1 reference

Europe PubMed Central

17 April 2018

http://europepmc.org/abstract/MED/17617271

Brian Woodfall

15

1 reference

Europe PubMed Central

17 April 2018

http://europepmc.org/abstract/MED/17617271

DUET-2 study group

16

1 reference

Europe PubMed Central

17 April 2018

http://europepmc.org/abstract/MED/17617271

language of work or name

0 references

publication date

1 July 2007

1 reference

Europe PubMed Central

17 April 2018

http://europepmc.org/abstract/MED/17617271

1 reference

Europe PubMed Central

17 April 2018

http://europepmc.org/abstract/MED/17617271

370

1 reference

Europe PubMed Central

17 April 2018

http://europepmc.org/abstract/MED/17617271

9581

1 reference

Europe PubMed Central

17 April 2018

http://europepmc.org/abstract/MED/17617271

39-48

1 reference

Europe PubMed Central

17 April 2018

http://europepmc.org/abstract/MED/17617271

Clinical utility of current NNRTIs and perspectives of new agents in this class under development

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961048-4

7 January 2021

based on heuristic

inferred from DOI database lookup

British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961048-4

7 January 2021

based on heuristic

inferred from DOI database lookup

The prevalence of antiretroviral drug resistance in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961048-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961048-4

7 January 2021

based on heuristic

inferred from DOI database lookup

TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961048-4

7 January 2021

based on heuristic

inferred from DOI database lookup

TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961048-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961048-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961048-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961048-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961048-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Codevelopment of new antiretrovirals in very treatment-experienced HIV-infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961048-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961048-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961048-4

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961048-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961048-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961048-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961048-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961048-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961048-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961048-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961048-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Epidemiology of antiretroviral drug resistance in drug-naïve persons

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961048-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961048-4

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961048-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(07)61048-4

1 reference

Europe PubMed Central

17 April 2018

http://europepmc.org/abstract/MED/17617271

release_sujombsftfb5za3nvmb3swtxma

1 reference

https://api.fatcat.wiki/v0/release/sujombsftfb5za3nvmb3swtxma

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

17 April 2018

http://europepmc.org/abstract/MED/17617271

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51910874&oldid=1835754345"